amubarvimab and romlusevimab (Investigational)

Brand and Other Names:BRII-196/BRII-198
  • Print
Sections

Dosing & Uses

COVID-19 (Investigational)

Pending EUA for treatment of mild-to-moderate coronavirus disease 2019 (COVID-19)

Next:

Pharmacology

Mechanism of Action

Amubarvimab/romlusevimab are monoclonal antibodies with non-overlapping epitope binding regions enabling a high degree of neutralization activity against SARS-CoV-2

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.